Aurobindo Pharma arm, Hilleman Labs Singapore ink pact for paediatric pentavalent vaccine

Published On 2023-09-28 07:00 GMT   |   Update On 2024-02-12 19:24 GMT
Advertisement

Telangana: Through a recent BSE filing, Aurobindo Pharma has informed that Auro Vaccines Private Limited, a wholly-owned subsidiary of the Company, has entered into a Licence Agreement with Hilleman Laboratories Singapore Pte. Limited to develop, manufacture and commercialize a pentavalent vaccine candidate used in children vaccination.

Auro Vaccines Private Limited will make milestone payments to Hilleman upon achieving certain development and clinical study outcomes. Hilleman will also be paid royalties upon commercialization of the vaccine candidate.

Advertisement

Read also: Aurobindo Pharma arm bags USFDA nod for Vancomycin Hydrochloride for Injection

"Please note that Auro Vaccines Private Limited is not a material subsidiary to the Company and the aforesaid entry into a Licence Agreement is not a material event. It may also be noted that at present entering into the aforesaid Licence Agreement will not have any significant impact on the Company and/or its subsidiaries or its financials. 
In the event of 
any significant impact in future, we will keep the exchanges informed about the same and provide necessary disclosures," Aurobindo Pharma stated in a BSE filing.

Pentavalent vaccine provides protection to a child from 5 life-threatening diseases – Diphtheria, Pertussis, Tetanus, Hepatitis B and Hib. 

Read also: USFDA tentative nod to Aurobindo Pharma's generic FDC drug to treat HIV in children

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 25 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s product portfolio is spread over multiple therapeutic/product areas encompassing CNS, AntiRetroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

Read also: Aurobindo Pharma arm secures USFDA okay for Icatibant Injection

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News